Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
Hirotsugu Kenmotsu(Shizuoka Cancer Center), Toshiaki Takahashi(Okayama University), Takehito Shukuya(Juntendo University), Nobuyuki Yamamoto(Wakayama Medical University), Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Kazushige Wakuda(Shizuoka Cancer Center), Satoru Miura(Niigata Cancer Center Hospital), Hidetoshi Hayashi(Kindai University), Koichi Azuma(Kyushu University Hospital), Keisuke Kirita(Hakodate Central General Hospital), Shunsuke Teraoka(Wakayama Medical University), Keita Mori(Shizuoka Cancer Center), Shunichi Sugawara(Sendai Kousei Hospital), Daichi Fujimoto(Hyogo University), Terufumi Kato(Taipei Veterans General Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Ryo Toyozawa(National Hospital Organization Kyushu Cancer Center), Ken Masuda(Hiroshima City Asa Citizens Hospital), Yasuto Yoneshima(Kyushu University)
Cited by 158
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k